Skip to main content

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.



) -- Investing in America never felt so good, Jim Cramer told his

Mad Money

 viewers Thursday. His new strategy for these turbulent markets is to invest in America first, and here's five good reasons reasons why.

1. Foreign currency wars. Cramer said trying to invest overseas where foreign currencies are constantly in flux is just getting too hard. Will Greece leave the euro? What happens to the Swiss if they no longer follow the euro? "Who knows?" quipped Cramer, which is why he's choosing to invest at home.

2. We're crushing it. Cramer said the U.S. is now the strongest economy in the world, and the runner-up isn't even close.

3. We innovate. Ever heard of a foreign electric car or an international shale oil driller? Cramer said America is leading in innovation in every industry that matters.

4. The strong dollar. With the dollar strong, Cramer said it's getting cheaper to buy goods from overseas, leading to higher margins and more profits for U.S. companies.

5. We have the goods. Cramer said the U.S. has the resources, the labor pool and the universities to keep the innovation going.

So what does all this mean to investors? Cramer said it means investing in U.S.-based restaurants, retail, real estate investment trusts, utilities and biotechs is the only game in town.

Next-Gen Biotech: Novavax

For the next installment of his week-long focus on "Biotech, The Next Generation," Cramer spoke with Stanley Erck, president and CEO of Novavax (NVAX) - Get Novavax, Inc. Report , a vaccine maker focused on RSV, a leader killer of infants, as well as the flu. Novavax also has an early stage Ebola vaccine under development.

Erck explained that Novavax's vaccine platform allows his company to make more potent vaccines faster than anyone. He noted that since sequencing the Ebola gene in September, the company has already successfully treated four species of animals and is moving rapidly towards primates and humans.

When it comes to the flu, Erck said Novavax has a platform that eliminates the guesswork that's common with current flu vaccines. He said the company's treatments are proving to be more potent across more strains of the flu.

TheStreet Recommends

And when it comes to RSV, which is a potent killer of infants under the age of one, Erck said the vaccines are generating a unique immune response that is also proving to be very effective in testing thus far.

When asked about possible partnerships, Erck said there is no shortage of partners out there, and once Novavax has an approved product it will certainly consider a partner.

Cramer said that while Novavax is a small and speculative stock, it's one investors should consider given its early successes.

Goodbye, Canada

"Thank God that's over." That was Cramer's response to Target's (TGT) - Get Target Corporation Report announcement that it's shuttering its Canadian operations at a cost of nearly $5.8 billion.

Cramer said Target's former CEO made one of the biggest blunders in corporate history by marching into Canada with 140 stores and simply hoping for the best. Canada is a very different animal than the U.S., Cramer explained. The arrogance and hubris exhibited by Target was not only astounding, but it nearly destroyed the company.

Compare that to Nordstrom (JWN) - Get Nordstrom, Inc. Report , another retailer that recently entered the Canadian market. Nordstrom opened one -- yes, just one -- store so it could test its concept and learn before attempting an expansion. No hubris there, Cramer said.

Cramer said he has a lot of faith in Target's current management team, and would even consider buying Target's stock at these levels because the company will most certainly do better in 2015 than it did in 2014.

Next-Gen Biotech: BioMarin

Continuing with his biotech focus, Cramer checked in with J.J. Bienaime, CEO of orphan drug maker BioMarin (BMRN) - Get BioMarin Pharmaceutical Inc. Report , a stock that's up 45% since Cramer last spoke with Bienaime in September.

Bienaime said the launch of Vimizim, a drug that may only treat 2,000 to 3,000 patients around the globe, is going better than expected and could represent a $1 billion opportunity for BioMarin. Without the drug, Bienaime said patients with the disease Marquio syndrome slowly lose their ability to walk, then to breath and ultimately have shorter life expectancies.

Bienaime also talked about BMN-673, a drug under development to treat a small subset of breast cancer patients. He said while this drug only treats a small fraction of breast cancer cases, it's having very successful results thus far.

Cramer said BioMarin has so many special things under development that it's easy to see why its stock is heading higher.

Lightning Round

In the Lightning Round, Cramer was bearish on Century Communities (CCS) - Get Century Communities, Inc. Report , Lennar (LEN) - Get Lennar Corporation Class A Report , Frontline (FRO) - Get Frontline Ltd. Report , Norfolk Southern (NSC) - Get Norfolk Southern Corporation Report and Mobileye (MBLY) .

Next-Gen Biotech: Receptos

For his third "Next Generation" biotech segment, Cramer spoke with Faheem Hasnain, president and CEO of Receptos (RCPT) , a stock that soared 322% in 2014 but has been pulling back so far this year, down 8.5% in today's session.

Hasnain talked about Receptos' primary drug, RPC1063, which is currently in Phase III testing. He explained that the drug helps control blood cells that have "gone haywire" and thus cause inflammation. This is beneficial for treating a number of inflammation-related disease including muscular sclerosis, Crohns' and inflammatory bowel disease and many other auto-immune diseases.

When asked about U.S. Food and Drug Administratoin approval, Hasnain said his company's current timeline is for 2018. But he did admit that faster approval is not outside the realm of possibility given that RPC1063 has fewer side effects than current treatments.

Cramer said this is a company that could "hit it out of the park."

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.

-- Written by Scott Rutt in Washington, D.C.

To email Scott about this article, click here: Scott Rutt

Follow Scott on Twitter


or get updates on Facebook,


At the time of publication, Cramer's Action Alerts PLUS had no position in stocks mentioned.